Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Benzinga

By James Blacker, Benzinga Some 42% of adults in the United States are affected by obesity, according to the U.S. CDC. At a global level, a new study released by the journal Lancet reveals that around 1 billion people are now living with obesity, with the number of obese adults having doubled since 1990 and quadrupled among children and adolescents. The demand for solutions to escalating obesity rates is only growing. Goldman Sachs Research notes that the global market for anti-obesity drugs reached $6 billion on an annualized basis in 2023 and this global market is projected to experience a more than 16-fold increase to $100 billion by 2030. The global growth of anti-obesity drugs is expected to be led by drugs such as Ozempic ® and Wegovy ®, both manufactured by Novo Nordisk (NYSE: NVO), as well as Mounjaro ®, made by Eli Lilly And Co (NYSE: LLY). However, there are concerns that GLP-1 drugs like Ozempic ® and Wegovy ® might lead to a loss of muscle mass along with fat mass. This potential side effect highlights a need for new or coinciding treatments that can address obesity while limiting such side effects. Revolutionizing Obesity Treatment Medical aesthetics and biopharmaceutical drug development company Elevai Labs Inc. (NASDAQ: ELAB) is working to address this problem. The firm announced on May 2 that it acquired exclusive rights to two new assets that have the potential to limit muscle loss prevention to develop in combination with GLP-1 obesity treatments – namely “EL-22”, a clinical-stage engineered probiotic expressing myostatin, and “EL-32”, a preclinical engineered probiotic expressing dual myostatin & activin-A. “We believe the adoption and use of other GLP-1 drugs […] increases the desire for related aesthetic procedures linked to the side effects from these drugs, including significant unwanted muscle loss. We see the licensing of these two assets as an opportunity to provide an unmet need in the anti-obesity drug market and expand our brand into a large and growing multi-billion-dollar market,” said Elevai Labs CEO Jordan R. Plews. Elevai plans to test how effective and safe EL-22 is in combination with weight-loss medications currently available on the market. It expects to submit an Investigational New Drug application to the FDA in 2025 and hopes to initiate clinical trials in the U.S. soon thereafter. New Subsidiaries In line with its growth in the biotech industry, Elevai Labs announced on May 1 it launched two new wholly-owned subsidiaries — Elevai Biosciences and Elevai Skincare. Elevai Biosciences will focus on acquiring and developing cutting-edge aesthetic medicines, with EL-22 as its lead asset. Elevai Skincare is a new entity that will continue to advance the company’s skincare solutions. The company hopes that the reorganization of its skincare operations will boost focus, agility, and market penetration in order to capitalize on emerging opportunities in the medical aesthetics skincare market. Commenting on the announcement, Co-founder and CEO Jordan R. Plews stated, “The launch of Elevai Biosciences, Inc. and Elevai Skincare, Inc. as wholly-owned operating subsidiaries signifies a significant milestone in our journey towards reshaping the future of medical aesthetics and biotech. With Elevai Biosciences, we believe we are poised to lead the development of next-generation aesthetic medicines, while Elevai Skincare will continue to develop and deliver exceptional cosmetic solutions to our customers worldwide.” Featured photo by Prostock-studio on Shutterstock. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. Cautionary Note Regarding Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "believes," "expects," "plans," "potential," "would" and "future" or similar expressions such as "look forward" are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: Elevai's expectations regarding its growth, strategy, progress and the design, objectives and timing of its clinical trials for EL-22; and the potential of EL-22 to treat obesity without an associated loss of muscle, both as a monotherapy and in combination with GLP-1 receptor agonists. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Elevai's limited operating history and historical losses; Elevai's ability to raise additional funding to complete the development and any commercialization of its product candidates; Elevai's dependence on the success of its product candidates EL-22 and EL-32; that Elevai may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Elevai's ability to obtain, maintain and protect its intellectual property; and Elevai's dependence on third parties in connection with manufacturing, clinical trials and preclinical studies. These and other risks are described more fully in Elevai's filings with the Securities and Exchange Commission ("SEC"), including the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

May 17, 2024 08:45 AM Eastern Daylight Time

Image

Neural Therapeutics CEO Ian Campbell discusses potential CSE listing and future plans

Neural Therapeutics Inc.

Neural Therapeutics CEO Ian Campbell discusses the company's conditional approval to list on the Canadian Securities Exchange (CSC) in an interview with Proactive's Stephen Gunnion. Campbell explained that the CSE listing is a strategic move, enabling broader market participation and capitalisation on its advancements. The company aims to raise $500,000, primarily for research and development efforts and securing intellectual property, including two patents. Campbell highlighted the growing interest in psychedelic treatments, noting the significant investment in this sector and the 44% rise of the Psychedelic Invest Index this year. He emphasised the mental health crisis and the inadequacy of outdated therapies, positioning psychedelics as a promising and disruptive alternative. Neural Therapeutics specialises in mescaline extracted from the San Pedro cactus, a substance with a long history of safe use. Campbell noted mescaline's unique properties, such as its longer duration in the body, which supports neuroplasticity and potential treatment for mental illnesses like addiction without causing hallucinations. The CSE listing is expected to enhance the company's visibility, attract investment, and accelerate drug development. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

May 17, 2024 08:00 AM Eastern Daylight Time

Video

Arecor Therapeutics reports strong 2023 results and outlines expanding product pipeline

Arecor Therapeutics PLC

Arecor Therapeutics PLC (AIM:AREC)C CEO Sarah Howell discusses the company's 2023 performance and future plans with Proactive's Stephen Gunnion. Howell highlighted that Arecor has seen significant growth, particularly with the launch of products incorporating its Arestat technology under a global licensing agreement, generating royalties. Six new technology partnerships were established with major pharma and biotech companies, offering potential for future licensing and market development. Arecor focuses on diabetes and obesity, with clinical results for their proprietary product, AT278, expected soon. This highly concentrated, rapid-acting insulin aims to provide better glucose control for type 2 diabetics with high BMI and support the next generation of insulin pump devices. Tetris Pharma, a subsidiary, has shown strong growth under new leadership, with product sales tripling to £2.9 million in 2023. Its lead product, glucagon, has contributed significantly to this growth. Howell also noted the importance of technology partnerships and licensing programs. Arecor has entered into three active license programs and is progressing well with its partners. One notable partnership is with Medtronic to develop a concentrated, stable insulin for intra-peritoneal delivery, aiming to reduce hospital visits for patients with brittle diabetes. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 17, 2024 03:20 AM Eastern Daylight Time

Video

Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day

Immunic Inc

Immunic Inc (NASDAQ:IMUX) chief scientific officer Hella Kohlhof joined Proactive's Stephen Gunnion on International Celiac Day, in the middle of Celiac Disease Awareness Month, to discuss the disease and the company’s developments in treating it. Kohlhof explained that celiac disease is a severe autoimmune disorder affecting around 1% of the global population, predominantly females. Unlike gluten intolerance, celiac disease involves an immune reaction to gluten, leading to gut inflammation and destruction. The only current treatment is a gluten-free diet, which is not effective for all patients. Kohlhof elaborated on the disease's scientific background, highlighting its genetic association with specific HLA genotypes (HLA-DQ2 and HLA-DQ8). She explained that celiac disease is triggered by the immune system's reaction to deaminated gluten peptides, causing inflammation and damage to the gut lining. Immunic is developing IMU-856, an epigenetic modulator, to treat gastrointestinal diseases like celiac disease. IMU-856 enhances gut regeneration and strengthens the gut barrier, improving patients' conditions. Kohlhof detailed the successful completion of a Phase 1b study in celiac patients, which demonstrated the drug’s safety, good pharmacokinetic properties, and positive effects on symptoms, biomarkers, gut histology, and nutrient uptake during a gluten challenge. The study confirmed the potential of IMU-856 in treating celiac disease, and further exploration of its mode of action is ongoing. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

May 16, 2024 05:54 PM Eastern Daylight Time

Video

Meritage Wealth Insurance Advisors Joins Forces with AmeriLife’s Saybrus Partners

AmeriLife

Saybrus Partners (“Saybrus”), a market leader in life and annuity distribution and an affiliate of AmeriLife Group, LLC (“AmeriLife”), announced today that it has entered into a partnership with Meritage Wealth Insurance Advisors (“Meritage”), a point-of-sale (POS) focused, national life insurance general agency that serves financial professionals across a spectrum of life, annuity, retirement, legacy and business/executive benefits planning solutions. Per the agreement, terms of the deal were not disclosed. “Meritage Wealth Insurance Advisors’ experience and success in the life insurance industry, sophisticated planning expertise, and strong operational capabilities make the firm an exciting complement to our business,” said Edward W. Cassidy, managing principal of Saybrus Partners. “I’m happy to welcome Meritage’s leadership team and employees to the Saybrus family, and look forward to our work together.” Founded in 2019 by a team of five industry veterans, Meritage has built a national reputation for expertly designed solutions and consistently exceeding expectations for the most sophisticated and complex client relationships. Among other capabilities, including point-of-sale support, Meritage’s full-service model offers access to advanced case design, deep carrier relationships and product options, and back-office and underwriting support. With over 100 years of combined experience, Meritage’s partners have built a company that is passionate about client service delivered through a high-touch, consultative approach that has helped the firm stand apart in the industry. “We are thrilled to be joining this industry-leading organization,” said Chuck Adam, one of Meritage’s founding partners. “Not only did we immediately connect with Saybrus’ culture and team, but the company’s strong track record, robust resources and long-standing relationships make it a great strategic fit for our firm.” Together with Saybrus, Meritage also becomes part of a fast-growing AmeriLife Wealth Group, a new kind of wealth distribution platform that aims to deliver a suite of best-in-class services to the modern agent and financial professional to ensure their clients – no matter their stage of life – never outgrow them. “Meritage brings all the components we look for in new wealth distribution partners and we’re thrilled to welcome them to the AmeriLife family of companies,” said Mike Vietri, Chief Distribution Officer for AmeriLife Wealth Group. “Indeed, Meritage is the perfect complement to Saybrus, and I have no doubt that – with the support of Ed and his team – Meritage will take an already stellar track record of growth and success to new heights.” Under Saybrus, the firm will continue to operate as a standalone company from its Cypress, Texas headquarters, led by its five founding partners who will report to Cassidy. ### About Meritage Wealth Insurance Advisors Meritage is a National Insurance General Agency with full support for client advisors managing important, sophisticated client relationships. Partnering with private and institutional practices, its team brings expertise in Family Planning, Legacy Planning, Retirement Planning and Business Planning. The firm’s comprehensive capabilities comprise point of sale consultation, advanced case design access, solutions from numerous life insurance carriers, high-end underwriting expertise and experienced case facilitation. For more information, visit www.meritagewia.com. About Saybrus Partners Saybrus Partners, LLC helps institutions and financial professionals address clients' needs with insurance and annuity solutions for basic protection as well as retirement, estate and business planning. Its partner firms include institutional financial advisories, insurance retailers, banks and broker/dealers. Customizing its services to best fit its partners' businesses, the company offers a complete set of distribution capabilities including assisted sales, traditional wholesaling, new business operations and custom product design. For more information, visit www.saybruspartners.com and follow Saybrus on LinkedIn. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and financial professionals and more than 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado media@amerilife.com Partnership Inquiries Patrick Nichols corporatedevelopment@amerilife.com Company Website https://amerilife.com/

May 16, 2024 09:00 AM Eastern Daylight Time

The HERizon Disposable Hysteroscope aims to redefine industry standards

Minerva Surgical, Inc.

Minerva Surgical announces the immediate and exclusive distribution of a new disposable hysteroscope that will be displayed at the Annual Clinical & Scientific Meeting of American College of Obstetricians and Gynecologists in San Francisco, CA. The company plans to soon rebrand the new disposable hysteroscope as HER izon, and their goal is to redefine the standards of efficiency and accessibility in gynecological care. “This marks a significant milestone in the company’s mission to address the needs of gynecologists and further advance Women’s Health,” states Minerva Surgical Chief Medical Officer Eugene Skalnyi, M.D. “ HER izon embodies versatility as a hysteroscope, facilitating an array of procedures both in the operating room and office settings. It is one of a few technologies that our team plans to launch to better serve the evolving patterns in Gynecology.” The HER izon Disposable Hysteroscope is a cutting-edge system that is introduced in alignment with ACOG and AAGL's advocacy for the elimination of blind assessment practices in the uterine cavity. Several key features of the HER izon Disposable Hysteroscope include. 1. Disposable Design: Single-use hysteroscope eliminates the need for traditional hysteroscope reprocessing, reduces the risk of cross-contamination, and ensures compliance with sterility standards. 2. Angled Cannula Tip: Provides rigidity to help enter the cervical canal and articulation to navigate an array of uterine cavity positions. 3. Compact Footprint: 4.8mm outer diameter sheath requires minimal or no dilation and 6Fr working channel allows for a broad spectrum of procedures such as direct visualization polypectomy, endometrial biopsy, D&C, and IUD removal. 4. User-Friendly Interface: High-Definition image technology, two LED lights provide bright and clear visualization, and the intuitive interface enables seamless system navigation. Dr. David Glassman, DO FACOG EMIGS, a prominent gynecologist in Phoenix, Arizona, shared his excitement about the new HER izon Disposable Hysteroscope, stating, “ HER izon is a revolutionary advancement in hysteroscopy technology. Designed with precision and patient comfort in mind, HER izon offers unparalleled clarity and control, providing healthcare professionals with a clearer view and easier access to the uterine cavity. Its innovative features enhance procedural efficiency, reducing both patient discomfort and procedure times. With HER izon, healthcare providers can elevate their practice, delivering superior care and empowering women to take control of their health with confidence.” The introduction of the HER izon Disposable Hysteroscope underscores Minerva Surgical’s commitment to providing gynecologists with solutions that improve patient outcomes. About Minerva Surgical, Inc. Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, distributing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. The Company has established a broad product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. The Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies. For more information about the HER izon Disposable Hysteroscope and other innovative medical devices from Minerva Surgical, please visit www.MinervaSurgical.com. The disposable hysteroscope is manufactured by Jiyuan Medical. Contact Details Minerva Surgical Kevin Tracey +1 855-646-7874 media@minervasurgical.com Company Website https://minervasurgical.com/

May 16, 2024 09:00 AM Eastern Daylight Time

UNOS applauds passage of FAA reauthorization bill

United Network for Organ Sharing

Today, the United Network for Organ Sharing (UNOS) issued its support of Congress’ passage of the bipartisan, bicameral Federal Aviation Administration (FAA) reauthorization bill, which includes a provision to improve the safety and efficiency of the transportation of donor organs through the nation’s commercial aviation system. The bill now heads to the president’s desk for signature. The Securing Growth and Robust Leadership in American Aviation Act requires the Department of Transportation (DOT), in consultation with the FAA, to convene a working group to develop best practices for transporting organs in the cabin of a commercial aircraft. The working group will include organ procurement organizations, transplant hospitals, commercial airlines, flight attendants and other federal agencies. DOT is required to convene the working group no later than 90 days after the bill is enacted. No later than one year after convening, the working group must present recommendations to the secretary of DOT. Before the September 11 attacks, organs – primarily kidneys – were transported within a commercial flight’s main cabin under supervision of the aircrew. The attacks prompted significant changes to airport protocols, including removing transplant professionals’ ability to accompany an organ through security without an airplane ticket. As a result, organs currently travel in the cargo hold and are subject to cargo business hours, which vary between airlines and are impacted by staffing shortages. Organs arriving when a cargo office is closed sit on ice for prolonged periods, increasing the potential for an organ not to be used. “Ensuring a donated organ gets to a patient on time and safely is absolutely critical, which is why UNOS has been working with the donation and transplant community and Congress to create a process to bring organs out of the cargo hold and back into the cabin of an airplane,” said Maureen McBride, Ph.D., CEO of UNOS. “Thank you to those working with us to advocate for change and include this provision in the FAA reauthorization package, namely Senators Ron Wyden, Maria Cantwell, Ted Cruz, and John Thune, and Reps. Bruce Westerman, Greg Stanton, Beth Van Duyne, Sam Graves, and Rick Larsen. The bill’s passage highlights the bipartisan consensus and understanding of the lifesaving importance of this issue. I appreciate the commitment to honor the gift of life and do right by patients on the waitlist, generous donors, and their families. I look forward to working with the Department of Transportation to bring organs back into the cabin of an aircraft.” Transportation is a cornerstone of the UNOS Action Agenda, a series of recommendations to strengthen the U.S. donation and transplant system. To further reduce the risk of delaying or damaging organs in transport, UNOS also recommends the next contracts for the Organ Procurement and Transplantation Network (OPTN) should require the use of physical trackers for unaccompanied donor organs recovered for transplant, and the establishment of a centralized organ tracking system. “Donations and transplants are going up across the country, and so are the number of organs traveling every hour of every day,” said McBride. “This community owes it to patients and donor families to ensure that organs travel as safely and efficiently as possible. Every viable organ ultimately not transplanted represents a profound loss.” The provision included in the FAA reauthorization bill is the result of ongoing advocacy by UNOS and other members of the nation’s organ donation and transplant community. Since 2022, UNOS has engaged with FAA leadership, the Transportation Security Administration and the House and Senate to pursue this reform. Actions to move organs back to the airplane cabin and out of cargo are widely endorsed by the donation and transplant community, including the American Association of Kidney Patients, American Foundation for Donation & Transplantation, American Kidney Fund, American Society of Histocompatibility and Immunogenetics, American Society of Nephrology, American Society of Transplantation, American Society of Transplant Surgeons, Association of Organ Procurement Organizations, Donate Life America, Donate Life Virginia, Kidney Care Partners, Kidney Transplant Collaborative, National Kidney Foundation, Nationwide Organ Recovery Transport Alliance, North American Transplant Coordinators Organization, Organ Donation Advocacy Group, Renal Physicians Association, Transplant Recipients International Organization, Transplant Families, Transplant Unwrapped, and Waitlist Zero. About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

May 15, 2024 02:53 PM Eastern Daylight Time

Delivra Health Brands releases Q3 financial number showing positive adjusted EBITDA

Delivra Health Brands Inc.

Delivra Health Brands CEO Gord Davey joined Steve Darling from Proactive to announce the financial and operating results for the three and nine months ended March 31, 2024. The company reported a total net revenue from continued operations of $8,792, reflecting a 36% increase compared to the same period last year, driven by higher sales of Dream Water in the US and Canada, along with increased sales of LivRelief. Additionally, Davey told Proactive, Delivra saw a healthy rise in its gross profit margin, reaching 52%, up from 44% in the same period last year. This improvement contributed to positive Adjusted EBITDA, attributed to management's focus on customer mix, gross profit margin enhancement, and efficient administrative and selling support functions. Contact Details Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

May 15, 2024 11:54 AM Eastern Daylight Time

Video

CONSENSUS HEALTH’S MARK A. RIEGER, MD NAMED AMONG NJBIZ MAGAZINE’S 2024 HEALTHCARE HEROES

Consensus Health

Consensus Health, a leading New Jersey-based healthcare organization with a physician-led medical group and an Independent Physician Alliance (IPA), announced today Mark A. Rieger, MD, senior partner physician, senior surgeon and medical group board member, was named a 2024 Healthcare Hero by NJBIZ Magazine, a leading business journal covering New Jersey. The Healthcare Heroes Awards program was created to recognize excellence, promote innovation and honor the efforts of individuals and organizations making a significant impact on the quality of health care throughout New Jersey. Submissions are reviewed and winners chosen by a panel of independent judges. The 2024 program recognized individuals and organizations across 11 categories. A pioneering pediatric orthopedic physician, Dr. Rieger is credited with many achievements that significantly impacted care – and continue to – for children across New Jersey. These accomplishments include, among others, introducing various, less invasive, diagnostic screening tools; creating physician groups led by acclaimed doctors; educating local healthcare professionals on specific diseases and care protocols; convincing local healthcare facilities to employ safer testing methods; and, holding leadership positions, all of which truly elevated pediatric orthopedic medical care statewide. “This honor means more than words can ever express. What I have always strived to do is to improve the lives of children faced with orthopedic challenges and ensure their safety throughout their patient journeys. I have been committed to this endeavor for 35 years, and the recognition I now earned from NJBIZ through their Healthcare Heroes Awards program is indicative of my unwavering desire to positively impact pediatric orthopedic care across the state. I am grateful to the judges and the entire Consensus Health Medical Group team, and of course, my patients and their families. You all are the reason I remain committed to improving quality of care and realizing positive patient outcomes, day in and day out,” Dr. Rieger explained. Michael Lovett, Consensus Health chief executive officer, commented: “Dr. Rieger and his unrelenting commitment to children throughout New Jersey has allowed Consensus Health Medical Group to truly stand out in the community. Patients from near and far travel to New Jersey to see Dr. Rieger and benefit from his distance expertise. We are privileged to have him as part of our group, and very proud of his accomplishments and contributions to the health of New Jersey children. From all of us at Consensus Health, we extend our sincerest congratulations to Dr. Rieger on this honor and thank him for his dedication to our patients.” NJBIZ Healthcare Heroes honorees will be recognized during an in-person awards ceremony on Tuesday, June 25 th, 8:00 AM – 10:30 AM at The Palace at Somerset Park. Accompanying the event will be a publication supplement highlighting their accomplishments. The supplement will be inserted into the July 8, 2024 issue of NJBIZ. About Consensus Health Marlton, New Jersey-based Consensus Health is a leading physician-owned and -governed medical group comprised of New Jersey-based independent primary care providers and specialty doctors. Consensus Health affords its 166 member physicians across 56 practices and 69 locations clinical autonomy, which enables them to focus on the delivery of high levels of patient care within the local markets they each serve. Currently, Consensus Health provides medical care statewide throughout 18 New Jersey counties. For more information, visit www.consensushealth.com or connect with the Company on LinkedIn. Contact Details PAIRELATIONS, LLC Susan J. Turkell +1 303-766-4343 sturkell@pairelations.com Company Website https://www.consensushealth.com/

May 15, 2024 08:00 AM Eastern Daylight Time

1 ... 28 29 30 31 32 ... 302